Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Conditions

The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Trial Timeline

Jul 31, 2024 → Mar 31, 2027

NCT ID

NCT06500247

About Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone

Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06500247. Target conditions include The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer.

What happened to similar drugs?

2 of 3 similar drugs in The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer were approved

Approved (2) Terminated (0) Active (1)

✅LetrozoleNovartisApproved

✅Cannabidiol (Epidiolex)Jazz PharmaceuticalsApproved

🔄DenosumabAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06500247	Phase 2	Recruiting	Jul 31, 2024	Mar 31, 2027	The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Competing Products

5 competing products in The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + 0.9% natural saline	Johnson & Johnson	Pre-clinical	22
Letrozole	Novartis	Approved	39
Denosumab	Amgen	Phase 3	40
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil	Akeso	Phase 2	31
Cannabidiol (Epidiolex)	Jazz Pharmaceuticals	Approved	40